Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-03-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于公司及控股子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about applying for a comprehensive credit facility with banks. It discusses the proposed credit amount, terms, and the board's authorization for the financing arrangement. There is no financial statement, earnings data, or detailed financial analysis present. The document is relatively short (1092 characters) and serves as a formal notice of financing activity rather than a full financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising or financing activities.
2025-03-10 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2024年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a special inspection report on the deposit and use of raised funds for the year 2024 by a securities company acting as the sponsor for a pharmaceutical company. It details the amount of funds raised, their usage, balances, management, and regulatory compliance related to the raised funds. The content includes detailed financial figures about fundraising, usage, and account balances, as well as regulatory references and agreements related to fund management. This type of document is a specialized audit or inspection report focusing on the use of raised capital, not a full annual report or earnings release. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on the use of funds raised by the company, including verification and compliance information. FY 2024
2025-03-10 Chinese
关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from 新天地药业股份有限公司 regarding the 2024年度利润分配预案 (2024 annual profit distribution plan). It details the proposed dividend payout per share, the basis of calculation, and the approval process by various company committees and the board. It also states that the proposal will be submitted to the 2024 annual shareholders meeting for approval. The document includes financial figures related to net profit, retained earnings, and dividend amounts, but it is primarily an announcement of the dividend plan rather than a full financial report or annual report. The document length is 3722 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on dividend distribution details and related approvals, fitting the definition of a Notice of Dividend Amount (DIV).
2025-03-10 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "新天地药业股份有限公司 2024 年年度报告" which translates to "Newland Pharmaceutical Co., Ltd. 2024 Annual Report." It contains detailed sections including company overview, financial data for the year 2024, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of audited financial statements, management discussion, and comprehensive financial indicators confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2024. Therefore, the document is classified as an Annual Report (10-K). FY 2024
2025-03-10 Chinese
致同会计师事务所（特殊普通合伙）关于新天地药业股份有限公司非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding non-operating fund occupation and other related party fund transactions for Xintiandi Pharmaceutical Co., Ltd. for the year 2024. It includes a detailed summary table of related party transactions and fund occupation balances, and it is addressed to an accounting firm with references to audit procedures and compliance with regulatory guidelines on listed company fund transactions. The document is signed by the accounting firm and company representatives and is intended for disclosure alongside the annual report. It is not the annual report itself, nor an earnings release or management discussion. It is a standalone audit-related report focusing on specific financial and regulatory compliance matters related to fund occupation and related party transactions. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report with detailed financial data and audit confirmation, but not the full annual report. FY 2024
2025-03-10 Chinese
关于公司及控股子公司使用部分闲置自有资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' use of idle funds for cash management, including details about the board and supervisory committee approvals, independent directors' opinions, and the sponsor's verification. It does not contain financial statements or detailed financial data but rather describes a corporate decision and related approvals. The document length is 2329 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full financial report, audit, or earnings release. It is a regulatory announcement about a corporate financing-related decision but not a direct capital raising or financing update. Given the content and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate governance and financial management decisions that do not fit other categories.
2025-03-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.